APO Research
Talk to an analyst

APO RESEARCH · REPORT

Parasitic Diseases Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Parasitic Diseases Therapeutic Market Outlook and Growth Opportunities 2026

20 December 2025192 pages

Choose your research edition.

Industry ResearchParasitic Diseases Therapeutic Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Parasitic Diseases Therapeutic Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Parasitic Diseases Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Parasitic Diseases Therapeutic Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Parasitic Diseases Therapeutic Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Parasitic Diseases Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Parasitic Diseases Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Parasitic Diseases Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Parasitic Diseases Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Parasitic Diseases Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Parasitic Diseases Therapeutic market include Pfizer, GlaxoSmithKline, Bayer, Sanaria and F. Hoffmann-La Roche, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Parasitic Diseases Therapeutic market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Parasitic Diseases Therapeutic and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Parasitic Diseases Therapeutic revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Parasitic Diseases Therapeutic market.

Parasitic Diseases Therapeutic Segment by Company

Pfizer

GlaxoSmithKline

Bayer

Sanaria

F. Hoffmann-La Roche

Parasitic Diseases Therapeutic Segment by Type

Acaricide

Insect Repellent

Peptides Medicine

Other

Parasitic Diseases Therapeutic Segment by Application

Commercial

Household

Parasitic Diseases Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Parasitic Diseases Therapeutic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Parasitic Diseases Therapeutic key companies, revenue, market share, and recent developments.

3. To split the Parasitic Diseases Therapeutic breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Parasitic Diseases Therapeutic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Parasitic Diseases Therapeutic significant trends, drivers, influence factors in global and regions.

6. To analyze Parasitic Diseases Therapeutic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parasitic Diseases Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Parasitic Diseases Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parasitic Diseases Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Parasitic Diseases Therapeutic industry.

Chapter 3: Detailed analysis of Parasitic Diseases Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Parasitic Diseases Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Parasitic Diseases Therapeutic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Parasitic Diseases Therapeutic Industry Trends Table 2. Parasitic Diseases Therapeutic Industry Drivers Table 3. Parasitic Diseases Therapeutic Industry Opportunities and Challenges Table 4. Parasitic Diseases Therapeutic Industry Restraints Table 5. Global Parasitic Diseases Therapeutic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Parasitic Diseases Therapeutic Revenue Share by Company (2021-2026) Table 7. Global Parasitic Diseases Therapeutic Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Parasitic Diseases Therapeutic Key Company Manufacturing Base & Headquarters Table 9. Global Parasitic Diseases Therapeutic Company, Product Type & Application Table 10. Global Parasitic Diseases Therapeutic Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Parasitic Diseases Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Acaricide Table 15. Significant Companies of Insect Repellent Table 16. Significant Companies of Peptides Medicine Table 17. Significant Companies of Other Table 18. Global Parasitic Diseases Therapeutic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Parasitic Diseases Therapeutic Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Parasitic Diseases Therapeutic Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Parasitic Diseases Therapeutic Sales Value Share by Type (2021-2026) Table 22. Global Parasitic Diseases Therapeutic Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Commercial Table 24. Significant Companies of Household Table 25. Global Parasitic Diseases Therapeutic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Parasitic Diseases Therapeutic Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Parasitic Diseases Therapeutic Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Parasitic Diseases Therapeutic Sales Value Share by Application (2021-2026) Table 29. Global Parasitic Diseases Therapeutic Sales Value Share by Application (2027-2032) Table 30. Global Parasitic Diseases Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Parasitic Diseases Therapeutic Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Parasitic Diseases Therapeutic Sales Value Share by Region (2021-2026) Table 33. Global Parasitic Diseases Therapeutic Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Parasitic Diseases Therapeutic Sales Value Share by Region (2027-2032) Table 35. Global Parasitic Diseases Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Parasitic Diseases Therapeutic Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Parasitic Diseases Therapeutic Sales Value Market Share by Country (2021-2026) Table 38. Global Parasitic Diseases Therapeutic Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Parasitic Diseases Therapeutic Sales Value Market Share by Country (2027-2032) Table 40. Pfizer Company Information Table 41. Pfizer Business Overview Table 42. Pfizer Parasitic Diseases Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Pfizer Parasitic Diseases Therapeutic Product Portfolio Table 44. Pfizer Recent Development Table 45. GlaxoSmithKline Company Information Table 46. GlaxoSmithKline Business Overview Table 47. GlaxoSmithKline Parasitic Diseases Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. GlaxoSmithKline Parasitic Diseases Therapeutic Product Portfolio Table 49. GlaxoSmithKline Recent Development Table 50. Bayer Company Information Table 51. Bayer Business Overview Table 52. Bayer Parasitic Diseases Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Bayer Parasitic Diseases Therapeutic Product Portfolio Table 54. Bayer Recent Development Table 55. Sanaria Company Information Table 56. Sanaria Business Overview Table 57. Sanaria Parasitic Diseases Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Sanaria Parasitic Diseases Therapeutic Product Portfolio Table 59. Sanaria Recent Development Table 60. F. Hoffmann-La Roche Company Information Table 61. F. Hoffmann-La Roche Business Overview Table 62. F. Hoffmann-La Roche Parasitic Diseases Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. F. Hoffmann-La Roche Parasitic Diseases Therapeutic Product Portfolio Table 64. F. Hoffmann-La Roche Recent Development Table 65. Research Programs/Design for This Report Table 66. Authors List of This Report Table 67. Secondary Sources Table 68. Primary Sources List of Figures Figure 1. Parasitic Diseases Therapeutic Product Image Figure 2. Global Parasitic Diseases Therapeutic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Parasitic Diseases Therapeutic Market Size (2021-2032) & (US$ Million) Figure 4. Global Parasitic Diseases Therapeutic Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Acaricide Image Figure 8. Insect Repellent Image Figure 9. Peptides Medicine Image Figure 10. Other Image Figure 11. Global Parasitic Diseases Therapeutic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Parasitic Diseases Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Parasitic Diseases Therapeutic Sales Value Share by Type (2021-2032) Figure 14. Commercial Image Figure 15. Household Image Figure 16. Global Parasitic Diseases Therapeutic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Parasitic Diseases Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Parasitic Diseases Therapeutic Sales Value Share by Application (2021-2032) Figure 19. Global Parasitic Diseases Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Parasitic Diseases Therapeutic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Parasitic Diseases Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 22. North America Parasitic Diseases Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Parasitic Diseases Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Parasitic Diseases Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Parasitic Diseases Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Parasitic Diseases Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Parasitic Diseases Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 28. South America Parasitic Diseases Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Parasitic Diseases Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Parasitic Diseases Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Acaricide
  • Insect Repellent
  • Peptides Medicine
  • Other
Applications
  • Commercial
  • Household
Companies covered
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • Sanaria
  • F. Hoffmann-La Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Parasitic Diseases Therapeutic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Parasitic Diseases Therapeutic Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Parasitic Diseases Therapeutic Market Dynamics
  1. 2.1 Parasitic Diseases Therapeutic Industry Trends
  2. 2.2 Parasitic Diseases Therapeutic Industry Drivers
  3. 2.3 Parasitic Diseases Therapeutic Industry Opportunities and Challenges
  4. 2.4 Parasitic Diseases Therapeutic Industry Restraints
3 Parasitic Diseases Therapeutic Market by Company
  1. 3.1 Global Parasitic Diseases Therapeutic Company Revenue Ranking in 2025
  2. 3.2 Global Parasitic Diseases Therapeutic Revenue by Company (2021-2026)
  3. 3.3 Global Parasitic Diseases Therapeutic Company Ranking (2024-2026)
  4. 3.4 Global Parasitic Diseases Therapeutic Company Manufacturing Base and Headquarters
  5. 3.5 Global Parasitic Diseases Therapeutic Company Product Type and Application
  6. 3.6 Global Parasitic Diseases Therapeutic Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Parasitic Diseases Therapeutic Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Parasitic Diseases Therapeutic Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Parasitic Diseases Therapeutic Market by Type
  1. 4.1 Parasitic Diseases Therapeutic Type Introduction
  2. 4.1.1 Acaricide
  3. 4.1.2 Insect Repellent
  4. 4.1.3 Peptides Medicine
  5. 4.1.4 Other
  6. 4.2 Global Parasitic Diseases Therapeutic Sales Value by Type
  7. 4.2.1 Global Parasitic Diseases Therapeutic Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Parasitic Diseases Therapeutic Sales Value by Type (2021-2032)
  9. 4.2.3 Global Parasitic Diseases Therapeutic Sales Value Share by Type (2021-2032)
5 Parasitic Diseases Therapeutic Market by Application
  1. 5.1 Parasitic Diseases Therapeutic Application Introduction
  2. 5.1.1 Commercial
  3. 5.1.2 Household
  4. 5.2 Global Parasitic Diseases Therapeutic Sales Value by Application
  5. 5.2.1 Global Parasitic Diseases Therapeutic Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Parasitic Diseases Therapeutic Sales Value by Application (2021-2032)
  7. 5.2.3 Global Parasitic Diseases Therapeutic Sales Value Share by Application (2021-2032)
6 Parasitic Diseases Therapeutic Regional Value Analysis
  1. 6.1 Global Parasitic Diseases Therapeutic Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Parasitic Diseases Therapeutic Sales Value by Region (2021-2032)
  3. 6.2.1 Global Parasitic Diseases Therapeutic Sales Value by Region: 2021-2026
  4. 6.2.2 Global Parasitic Diseases Therapeutic Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Parasitic Diseases Therapeutic Sales Value (2021-2032)
  7. 6.3.2 North America Parasitic Diseases Therapeutic Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Parasitic Diseases Therapeutic Sales Value (2021-2032)
  10. 6.4.2 Europe Parasitic Diseases Therapeutic Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Parasitic Diseases Therapeutic Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Parasitic Diseases Therapeutic Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Parasitic Diseases Therapeutic Sales Value (2021-2032)
  16. 6.6.2 South America Parasitic Diseases Therapeutic Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Parasitic Diseases Therapeutic Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Parasitic Diseases Therapeutic Sales Value Share by Country, 2025 VS 2032
7 Parasitic Diseases Therapeutic Country-level Value Analysis
  1. 7.1 Global Parasitic Diseases Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Parasitic Diseases Therapeutic Sales Value by Country (2021-2032)
  3. 7.2.1 Global Parasitic Diseases Therapeutic Sales Value by Country (2021-2026)
  4. 7.2.2 Global Parasitic Diseases Therapeutic Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Parasitic Diseases Therapeutic Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Parasitic Diseases Therapeutic Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Parasitic Diseases Therapeutic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Parasitic Diseases Therapeutic Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Parasitic Diseases Therapeutic Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Parasitic Diseases Therapeutic Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Parasitic Diseases Therapeutic Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Parasitic Diseases Therapeutic Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Parasitic Diseases Therapeutic Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Sanaria
  20. 8.4.1 Sanaria Company Information
  21. 8.4.2 Sanaria Business Overview
  22. 8.4.3 Sanaria Parasitic Diseases Therapeutic Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanaria Parasitic Diseases Therapeutic Product Portfolio
  24. 8.4.5 Sanaria Recent Developments
  25. 8.5 F. Hoffmann-La Roche
  26. 8.5.1 F. Hoffmann-La Roche Company Information
  27. 8.5.2 F. Hoffmann-La Roche Business Overview
  28. 8.5.3 F. Hoffmann-La Roche Parasitic Diseases Therapeutic Revenue and Gross Margin (2021-2026)
  29. 8.5.4 F. Hoffmann-La Roche Parasitic Diseases Therapeutic Product Portfolio
  30. 8.5.5 F. Hoffmann-La Roche Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst